Incyte, Hengrui In 'Biggest Ever' China Pharma Out-Licensing Deal
This article was originally published in Scrip
In an alliance that illustrates the growing attractiveness of rising innovative R&D capabilities at selected Chinese pharma firms, the US oncology-focused company Incyte Corp. has acquired development and commercialization rights in most global markets to SHR-1210, a PD-1-targeting antibody developed by Jiangsu Hengrui Medicine Co. Ltd.
You may also be interested in...
Incyte's potential $900m licensing agreement with MacroGenics for its clinical-stage checkpoint inhibitor is considered a strong strategic move for Incyte, with the PD-1 inhibitor, MGA012, likely to become a cornerstone of its immune-oncology combination cancer therapies.
Fosun Pharma and Shanghai Pharma have both officially denied their involvement in any bidding battle for German company Stada, although both Chinese firms make no secret of their international expansion ambitions and have been active deal makers in the past.
China’s Jiangsu Hengrui Medicine is accelerating its move towards innovation by increasing investment and partnerships, as part of a strategy to shift its focus away from its traditional generic business. It is now providing substantial funding to a new US-based spinoff aiming to develop oncology biologics and immunotherapies and to act as an innovation bridge between the US and China.